Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Decitabine-primed Tandem Targeting CD19 and CD20 Chimeric Antigen Receptor T Cells Treatment in Relapsed and/or Refractory Non-Hodgkin's Lymphoma Patients

NCT04697940 is registered in ClinicalTrials.gov with Han weidong as lead sponsor.

NCT NCT04697940
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04697940 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Decitabine-primed Tandem Targeting CD19 and CD20 Chimeric Antigen Receptor T Cells Treatment in Relapsed and/or Refractory Non-Hodgkin's Lymphoma Patients
Lead sponsor
Han weidong
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
April 15, 2021
Completion date
September 1, 2026
Enrollment
33 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

decitabine-primed tandem cd19/cd20 car t cells, relapsed and refractory b-cell non-hodgkin's lymphoma